Observational studyEuropean archives of psychiatry and clinical neuroscience2026
Clinical deep phenotyping of treatment response in schizophrenia (CDP-STAR): design and methodology of a prospective multimodal observational study.
Observational study in European archives of psychiatry and clinical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Investigating changes in the blood-brain barrier in schizophrenia spectrum disorders: design and methodology of a longitudinal dynamic contrast-enhanced MRI study.European archives of psychiatry and clinical neuroscience · 2026Article
- Brain-body interactions in systemic diseases: a survey from an imaging perspective.MedScience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia spectrum disorders (SSDs) exhibit a marked heterogeneity in clinical course and treatment outcomes. Some individuals achieve remission and recovery, whereas others experience repeated relapses and progressive deterioration in psychosocial functioning. This variability underscores the unmet clinical need for prognostic biomarkers to predict treatment outcomes and guide personalized care. Deep phenotyping with multimodal data integration holds promise for understanding this complexity and delivering clinically relevant predictive models of treatment response in SSDs. To address this need, we initiated the Clinical Deep Phenotyping of Treatment Response in Schizophrenia (CDP-STAR) study, a prospective, naturalistic, longitudinal observational study integrating comprehensive multimodal assessments. These include clinical phenotyping, magnetic resonance imaging (MRI), electroencephalography (EEG), retinal imaging, and extensive sampling of blood and cerebrospinal fluid (CSF) for multi-omics profiling. The study aims to externally validate promising biomarker candidates and elucidate the pathophysiological mechanisms underlying treatment outcomes. This innovative deep phenotyping framework integrates data across multiple critical domains, enabling external validation of potential biomarkers and the discovery of novel ones. Ultimately, the CDP-STAR study aims to yield mechanistic insights that advance precision psychiatry and inform clinical decision-making in SSDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.